Recipharm Appoints New Directors, Business Management to Further Strengthen European Sales Drive
Recipharm has appointed two new Directors of Business Management. These appointments form part of Recipharm’s strategic drive to increase the volume of its business and revenues in key European markets.
Henning Neubauer has joined the Business Management team at Recipharm, taking on the position of Business Director for Northern Germany and the Netherlands. In parallel, Antonio Lopez also joins the team in the role of Business Director for Spain and Southern France.
Previously, Neubauer was Chief Operating Officer (COO) at a German start-up company in Hamburg dealing with generic products, OTC and Rx. Prior to that, he worked for more than 10 years at Haupt Pharma as Head of Customer Service and Sales, responsible for leading the Customer Service Team and key account management. He has a degree and Diploma in Marketing from the Open University of Bad Harzburg.
Antonio Lopez, has previous experiences in Business Development and partnering, logistics, compliance and regulatory activities in the role as VP of Operations in Flavine, a US trading company involved in generics APIs and finished dosage forms. Prior to this, he worked for more than 20 years at the Spanish pharmaceutical company Grupo Uriach. Antonio graduated with a Pharmacist degree from the University of Barcelona and holds a Masters in Business Administration from Barcelona’s Esade Business School.
As a further initiative to bolster the Business Management organisation, Åsa Wilander joined the team in mid-January in the new role of Key Account Director for the Nordic region. In this role, Åsa will be responsible for co-ordinating customer management and commercial aspects, as well as developing relationships with a selected number of customers. Åsa has been with Recipharm since 2007. To date, she has been working as General Manager of the Höganäs facility and led a significant expansion of the company. She has some 30 years experience of the pharmaceutical industry including the leadership of a contract manufacturing supply team at Pfizer.
Commenting on the new appointments, Kenth Berg, VP Business Management Recipharm, stated: “I am very pleased to have such talent join our business management structure. Europe is one of our key markets and we look forward to utilising the respective skills and expertise of Henning and Antonio to further enhance our European sales drive in Germany, the Netherlands and Spain.”
He continued: “Indeed post our recent IPO, this is an exciting time to plan ahead and expand our revenues and turnover across our international operations of which Europe is a highly important component”.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.